AbbVie spends $60M, with $80.5M in biobucks, for Alpine Immune’s lupus asset
Seattle-based Alpine Immune Sciences announced a $60M licensing agreement with AbbVie Inc. for its ALPN-101 midstage lupus and autoimmune asset. Under the pact, AbbVie grabs the rights to the experimental therapy and could pay up to $805 million in biobucks, as well as royalties, should the med gain approval.